Search Result
Results for "
acidic-pH
" in MedChemExpress (MCE) Product Catalog:
9
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P0014
-
-
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
-
- HY-B1329
-
|
Nebramycin II sulfate
|
Bacterial
Antibiotic
|
Infection
|
|
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .
|
-
-
- HY-P3462A
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
-
- HY-128144
-
|
|
Lipase
|
Metabolic Disease
|
|
Lalistat 2 is an inhibitor of many lipases especially Lysosomal acid lipase (LAL, IC50 = 152 nM), which is a key enzyme that degrades neutral lipids at an acidic pH in lysosomes. Lalistat 2 is commonly used to investigate the cell-specific functions of LAL and LAL deficiency in vitro, as well as specifically measure LAL activity in human blood samples or cells .
|
-
-
- HY-P10272
-
|
PTG-300
|
Ferroportin
|
Others
|
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
-
- HY-P2863
-
|
DNase II
|
Endonuclease
|
Others
|
|
Deoxyribonuclease II (DNase II) is an endonuclease that hydrolyzes the phosphodiester bonds of deoxyribonucleotides in native and denatured DNA, producing 3' phosphate and 5'-hydroxyl termini. Deoxyribonuclease II works best at acidic pH and is commonly used in biochemical research .
|
-
-
- HY-W039911
-
|
PNP-alpHa-D-Gal; PNP-α-D-Gal
|
Biochemical Assay Reagents
|
Others
|
|
4-Nitrophenyl α-D-galactopyranoside (PNP-alpha-D-Gal) is an artificial substrate of 4-nitrophenyl (pNP) glycopyranoside for detecting α-galactosidase activity. The amount of released pNP is significantly increased when 4-Nitrophenyl α-D-galactopyranoside is used as substrates .
|
-
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
-
- HY-13451
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Finafloxacin is an orally active fourth-generation fluoroquinolone broad-spectrum antibiotic. Finafloxacin exhibits stronger antibacterial activity in acidic pH environments and is not easily affected by bacterial multidrug efflux transporters. Finafloxacin is effective against a variety of extracellular pathogenic bacteria, and can also accumulate in macrophages, showing excellent antibacterial activity against intracellular Staphylococcus aureus, Listeria monocytogenes, Legionella pneumophila, Burkholderia pseudomallei, and other pathogens. Finafloxacin has been approved by the U.S. FDA for research on acute otitis externa mediated by Pseudomonas aeruginosa. Finafloxacin is also used in studies related to diseases such as melioidosis, inhalational tularemia, and inhalational plague .
|
-
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
-
- HY-W111692
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Sodium polyphosphate, crystal,+200 mesh, 96% is an inorganic polyphosphate that also serves as a stabilizer, dispersant, chelating agent, and coacervate-forming agent. Sodium polyphosphate provides electrostatic stabilization for mineral and material suspensions, but its dispersing efficacy decreases under acidic pH, high temperature, high calcium concentration, or a combination of these conditions. Sodium polyphosphate can chelate alkaline earth metals, reduce solution pH, and alter the rate of pH decline at a divalent cation/phosphorus molar ratio of 0.18. Sodium polyphosphate forms coacervates with smaller divalent cations and precipitates with larger divalent cations, where the functional requirements of cations depend on polyphosphate concentration, average degree of polymerization, and cation type .
|
-
-
- HY-P10218
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P0014S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
GCGR
|
Others
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P10271
-
|
NNC0090-2746; MAR709; RO6811135
|
GLP Receptor
|
Metabolic Disease
|
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
-
- HY-P10031
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .
|
-
-
- HY-P10218A
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
-
- HY-P0014B
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
|
-
-
- HY-P3143
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
-
- HY-P11273
-
-
-
- HY-153476A
-
|
|
GLP Receptor
GCGR
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-153476
-
|
|
GCGR
GLP Receptor
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-P11290
-
-
-
- HY-W243460
-
|
|
Biochemical Assay Reagents
|
Others
|
|
EDTA copper (II) disodium salt, 97% is a negatively charged copper (II)-ethylenediaminetetraacetic acid chelate and also an adsorption substrate. EDTA copper (II) disodium salt, 97% forms amide bonds with chitosan amino groups in weakly acidic (pH 3-5) solutions, while it forms the CuEDTA (OH) 3− hydroxyl complex in strongly alkaline (pH > 12) solutions. EDTA copper (II) disodium salt, 97% can be adsorbed onto granular activated carbon, with electrostatic interactions dominating its pH-dependent adsorption behavior. EDTA copper (II) disodium salt, 97% can be used to eliminate the inhibition of enzyme-catalyzed reactions caused by trace heavy metals .
|
-
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
-
- HY-167015
-
|
|
Liposome
|
Others
|
|
1O14 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 1O14 can be used in the preparation of liposomes .
|
-
-
- HY-167012
-
|
|
Liposome
|
Others
|
|
306Oi9-cis2 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 306Oi9-cis2 can be used in the preparation of liposomes .
|
-
-
- HY-B1329R
-
|
Nebramycin II sulfate (Standard)
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
|
-
-
- HY-169089
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
-
- HY-P10563
-
|
BHV-1100
|
CD38
|
Cancer
|
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
-
- HY-17558
-
|
Nebramycin II
|
Bacterial
Antibiotic
|
Infection
|
|
Apramycin (Nebramycin II) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .
|
-
-
- HY-P11233
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
|
-
-
- HY-P0014AS
-
-
-
- HY-P10031A
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .
|
-
-
- HY-169089A
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
-
- HY-P0014A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .
|
-
-
- HY-P10318
-
|
|
GLP Receptor
|
Endocrinology
|
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
-
- HY-P1614
-
-
-
- HY-P0041A
-
-
-
- HY-P0014S2
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P3143A
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
-
- HY-113560
-
-
-
- HY-P1162
-
-
-
- HY-P10910
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .
|
-
-
- HY-P11243
-
|
|
Ephrin Receptor
|
Neurological Disease
|
|
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
|
-
-
- HY-167004A
-
|
|
Liposome
|
Others
|
|
IAJD249 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD249 can be used in the preparation of liposomes .
|
-
-
- HY-167004
-
|
|
Liposome
|
Others
|
|
IAJD93 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD93 can be used in the preparation of liposomes .
|
-
-
- HY-167003
-
|
|
Liposome
|
Others
|
|
L16 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. L16 can be used in the preparation of liposomes .
|
-
-
- HY-167011
-
|
|
Liposome
|
Others
|
|
Al-28 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. Al-28 can be used in the preparation of liposomes .
|
-
- HY-P11055
-
|
|
Bacterial
|
Infection
|
|
IKFQFHFD is a pH-responsive and self-assembling peptide. IKFQFHFD is biocompatible at neutral pH and becomes an antimicrobial peptide-like molecular structure only at acidic pH. IKFQFHFD can be used for chronic wounds (venous ulcers, diabetic ulcers, and pressure ulcers) induced by biofilm infections research .
|
-
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P10869
-
dCNP
1 Publications Verification
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
-
- HY-P10200
-
|
|
Bacterial
|
Infection
|
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P0041
-
-
- HY-P5161
-
-
- HY-P5161A
-
-
- HY-109166
-
-
- HY-P11279
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .
|
-
- HY-P2595
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
-
- HY-P10881
-
-
- HY-167002
-
|
|
Liposome
|
Others
|
|
RM 137-15 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. RM 137-15 can be used in the preparation of liposomes .
|
-
- HY-D2998
-
|
|
Fluorescent Dye
|
Others
|
|
ONOO-LysopH is a new Rhodamine-based near-infrared fluorescent probe. ONOO-LysopH is acid-sensitive, exhibiting rapid near-infrared fluorescence enhancement around 686 nm under acidic pH conditions. ONOO-LysopH also displays a rapid NIR turn-on fluorescence around 678 nm for ONOO− at physiological pH. ONOO-LysopH can target lysosomes to track lysosomal pH changes and image endogenous/exogenous ONOO− in live cells. ONOO-LysopH is applicable for cell imaging ONOO− and tracking lysosomal pH changes .
|
-
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
-
- HY-N17580
-
|
|
Renin
|
Cardiovascular Disease
|
|
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .
|
-
- HY-P11604
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC50 values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .
|
-
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
-
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-D2998
-
|
|
Fluorescent Dyes
|
|
ONOO-LysopH is a new Rhodamine-based near-infrared fluorescent probe. ONOO-LysopH is acid-sensitive, exhibiting rapid near-infrared fluorescence enhancement around 686 nm under acidic pH conditions. ONOO-LysopH also displays a rapid NIR turn-on fluorescence around 678 nm for ONOO− at physiological pH. ONOO-LysopH can target lysosomes to track lysosomal pH changes and image endogenous/exogenous ONOO− in live cells. ONOO-LysopH is applicable for cell imaging ONOO− and tracking lysosomal pH changes .
|
| Cat. No. |
Product Name |
Type |
-
- HY-W039911
-
|
PNP-alpHa-D-Gal; PNP-α-D-Gal
|
Biochemical Assay Reagents
|
|
4-Nitrophenyl α-D-galactopyranoside (PNP-alpha-D-Gal) is an artificial substrate of 4-nitrophenyl (pNP) glycopyranoside for detecting α-galactosidase activity. The amount of released pNP is significantly increased when 4-Nitrophenyl α-D-galactopyranoside is used as substrates .
|
-
- HY-W111692
-
|
|
Biochemical Assay Reagents
|
|
Sodium polyphosphate, crystal,+200 mesh, 96% is an inorganic polyphosphate that also serves as a stabilizer, dispersant, chelating agent, and coacervate-forming agent. Sodium polyphosphate provides electrostatic stabilization for mineral and material suspensions, but its dispersing efficacy decreases under acidic pH, high temperature, high calcium concentration, or a combination of these conditions. Sodium polyphosphate can chelate alkaline earth metals, reduce solution pH, and alter the rate of pH decline at a divalent cation/phosphorus molar ratio of 0.18. Sodium polyphosphate forms coacervates with smaller divalent cations and precipitates with larger divalent cations, where the functional requirements of cations depend on polyphosphate concentration, average degree of polymerization, and cation type .
|
-
- HY-167015
-
|
|
Biochemical Assay Reagents
|
|
1O14 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 1O14 can be used in the preparation of liposomes .
|
-
- HY-167012
-
|
|
Biochemical Assay Reagents
|
|
306Oi9-cis2 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 306Oi9-cis2 can be used in the preparation of liposomes .
|
-
- HY-167004A
-
|
|
Biochemical Assay Reagents
|
|
IAJD249 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD249 can be used in the preparation of liposomes .
|
-
- HY-167004
-
|
|
Biochemical Assay Reagents
|
|
IAJD93 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD93 can be used in the preparation of liposomes .
|
-
- HY-167003
-
|
|
Biochemical Assay Reagents
|
|
L16 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. L16 can be used in the preparation of liposomes .
|
-
- HY-167011
-
|
|
Biochemical Assay Reagents
|
|
Al-28 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. Al-28 can be used in the preparation of liposomes .
|
-
- HY-167002
-
|
|
Biochemical Assay Reagents
|
|
RM 137-15 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. RM 137-15 can be used in the preparation of liposomes .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0014
-
-
- HY-P3462
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide is an investigational novel long-acting acylated amylin analogue, acts as nonselective amylin receptors (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Cagrilintide induces significant weight loss and reduces food intake. Cagrilintide has the potential for the research of obesity .
|
-
- HY-P3462A
-
|
|
CGRP Receptor
|
Metabolic Disease
|
|
Cagrilintide acetate is a non-selective AMYR/CTR agonist and long-acting acylated amylase analogue. Cagrilintide acetate causes a reduction in food intake and significant weight loss in a dose-dependent manner. Cagrilintide acetate can be used in obesity studies .
|
-
- HY-P10272
-
|
PTG-300
|
Ferroportin
|
Others
|
|
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
|
-
- HY-P2231
-
|
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P2231A
-
|
MEDI0382 acetate
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
|
-
- HY-P4116
-
|
pHLIP
|
Peptides
|
Metabolic Disease
Cancer
|
|
pH-Low Insertion Peptide (pHLIP) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide successfully modify polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide-based targeting of cancer presents an opportunity to monitor metabolic changes, and to selectively deliver imaging and therapeutic agents to tumors .
|
-
- HY-P3291
-
|
ZP7570
|
GCGR
|
Metabolic Disease
|
|
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects .
|
-
- HY-P10218
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0014S1
-
|
|
Isotope-Labeled Compounds
GLP Receptor
GCGR
|
Others
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
- HY-P10271
-
|
NNC0090-2746; MAR709; RO6811135
|
GLP Receptor
|
Metabolic Disease
|
|
RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
|
-
- HY-P10031
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity .
|
-
- HY-P10218A
-
|
|
MARCKS
PKC
|
Inflammation/Immunology
Cancer
|
|
MANS peptide TFA is the TFA salt form of MANS peptide (HY-P10218). MANS peptide TFA is an inhibitor for myristoylated alanine-rich C kinase substrate (MARCKS), which competes with MARCKS in cells for membrane binding, and thus inhibits the stimulation of mucin secretion and tumor metastasis .
|
-
- HY-P0014B
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .
|
-
- HY-P3143
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P11273
-
-
- HY-153476A
-
|
|
GLP Receptor
GCGR
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 sodium is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 sodium is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
- HY-153476
-
|
|
GCGR
GLP Receptor
|
Inflammation/Immunology
|
|
GIP/GLP-1 dual receptor agonist-1 is a GIP/GLP-1 dual receptor agonist. GIP/GLP-1 dual receptor agonist-1 is used in the research of metabolic disorders and fatty liver diseases, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) .
|
-
- HY-P11290
-
-
- HY-P10341
-
|
|
GCGR
|
Metabolic Disease
|
|
ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
|
-
- HY-P4116A
-
|
pHLIP TFA
|
Peptides
|
Metabolic Disease
Cancer
|
|
pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors .
|
-
- HY-169089
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K palmitic acid-NH2 (Compound 1a) is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K palmitic acid-NH2 inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K palmitic acid-NH2 exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
- HY-P10563
-
|
BHV-1100
|
CD38
|
Cancer
|
|
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
|
-
- HY-P11233
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Acmopatide (Compound E-153) is a dual-acting GIP/GLP-1 receptor agonist. Acmopatide is used in anti-diabetic research .
|
-
- HY-P0014AS
-
-
- HY-P10031A
-
|
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity .
|
-
- HY-169089A
-
|
|
Drug Derivative
|
Cancer
|
|
RP-182-PEG3-K(palmitic acid)-NH2 (Compound 1a) TFA is a fatty acid derivative of the immunomodulatory peptide RP-182. RP-182-PEG3-K(palmitic acid)-NH2 TFA inhibits CD206 high M2-like macrophage (IC50 of 3.2 μM) and induces phagocytosis. RP-182-PEG3-K(palmitic acid)-NH2 TFA exhibits antitumor efficacy in mouse B16 melanoma allografts .
|
-
- HY-P0014A
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Liraglutide acetate is the acetate form of Liraglutide (HY-P0014), a glucagon-like peptide-1 (GLP-1) receptor agonist studied in type 2 diabetes .
|
-
- HY-P10318
-
|
|
GLP Receptor
|
Endocrinology
|
|
SHR-2042 is a selective agonist of the GLP-1 receptor.SHR-2042 improves glycemic control by activating the GLP-1 receptor, enhancing insulin secretion and inhibiting glucagon secretion. SHR-2042 combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) promotes monomerization through the formation of micelles and improves oral absorption efficiency .
|
-
- HY-P1614
-
-
- HY-P0041A
-
-
- HY-P0014S2
-
|
|
Isotope-Labeled Compounds
|
Others
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
- HY-P3143A
-
|
|
PD-1/PD-L1
|
Cancer
|
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-113560
-
-
- HY-P1162
-
-
- HY-P10910
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
Vensemaglutide is the agonist for glucagon-like peptide 1 (GLP-1) receptor. Vensemaglutide can be used in research of diabetes or other metabolic disorders .
|
-
- HY-P11243
-
|
|
Ephrin Receptor
|
Neurological Disease
|
|
EphA4 agonist compound 23 is a novel EphA4 agonist peptide mimic. EphA4 agonist compound 23 exhibits high affinity, high selectivity, and significant receptor activation ability. EphA4 agonist compound 23 is commonly used in the study of neurodegenerative diseases .
|
-
- HY-P11055
-
|
|
Bacterial
|
Infection
|
|
IKFQFHFD is a pH-responsive and self-assembling peptide. IKFQFHFD is biocompatible at neutral pH and becomes an antimicrobial peptide-like molecular structure only at acidic pH. IKFQFHFD can be used for chronic wounds (venous ulcers, diabetic ulcers, and pressure ulcers) induced by biofilm infections research .
|
-
- HY-P10876
-
|
|
Amyloid-β
|
Neurological Disease
|
|
mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
|
-
- HY-P10869
-
dCNP
1 Publications Verification
|
Natriuretic Peptide Receptor (NPR)
|
Inflammation/Immunology
Cancer
|
|
dCNP binds to NPR-B/C receptor, activates cGMP signaling pathway, and regulates vascular function. dCNP exhibits anti-hypoxia property through downregulation of hypoxia-related genes expressions like HIF1α and HIF2α. dCNP inhibits the induction of tumor stroma and exhibits anti-fibrosis activity. dCNP upregulates CTLs, NK cells, and conventional type 1 dendritic cells in tumors, and activates immune responses .
|
-
- HY-P4837
-
|
|
Peptides
|
Others
|
|
Ac-Lys-D-Ala-D-lactic acid is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .
|
-
- HY-P10200
-
|
|
Bacterial
|
Infection
|
|
CP7-FP13-2 is a peptide with antivirulence factor and antibacterial activity. CP7-FP13-2 inhibits the formation of Staphylococcus aureus biofilm and has good antibacterial efficacy in mice .
|
-
- HY-P0041
-
-
- HY-P5161
-
-
- HY-P5161A
-
-
- HY-109166
-
-
- HY-P11279
-
|
|
GLP Receptor
GCGR
Neuropeptide Y Receptor
|
Metabolic Disease
|
TC2 is an efficient GIPR-preferring monomeric quadruple agonist that can respectively activate GIPR, GLP-1R, GcgR, and Y2R with IC50 values of 0.47, 2.1, 30, and 55 nM respectively. TC2 exhibits a significant GLP-1R preference, with a significant reduction in β-inhibitory protein 2 (βArr2) recruitment, while maintaining a strong cAMP signal. TC2 can be used for research on obesity and diabetes .
|
-
- HY-P10381
-
|
|
Peptides
|
Others
|
|
palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC50: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .
|
-
- HY-P2595
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
SKF 103784 is an vasopressin antagonist with activity against vasopressin. SKF 103784 inhibits the physiological response caused by antidiuretic and is therefore used to study biological processes related to water and salt balance. SKF 103784 can also be used to explore pathological mechanisms related to cardiovascular diseases and endocrine dysfunction .
|
-
- HY-P10881
-
- HY-P11784
-
|
|
Peptides
|
Others
|
|
p5RHH is an acid-activated membrane-lytic peptide derived from melittin. p5RHH, as a siRNA delivery vector, initiates synchronous disassembly of nanocomplexes and endosome lysis in response to acidic pH, and triggers the release of siRNA into the cytoplasm following macropinocytosis .
|
- HY-P11759
-
|
|
Drug Derivative
|
Cancer
|
|
Myr-transportan-Cys is a derivative of the cell-penetrating peptide Transportan (HY-P1732), and its conjugated myristoyl group (Myr) enhances the interaction between the peptide and cell membranes. Myr-transportan-Cys integrates three key delivery functions: nucleic acid condensation, cell penetration, and endosomal escape. Myr-transportan-Cys can form immunostimulatory tandem peptide nanocomplexes (iTPNCs) for encapsulating and delivering immunostimulatory oligonucleotide cargos to tumors .
|
- HY-N17580
-
|
|
Renin
|
Cardiovascular Disease
|
|
Lyciumin D acts as an angiotensin-converting enzyme inhibitor and renin inhibitor. Lyciumin D can be used for the research of hypertension .
|
- HY-P11604
-
|
|
Phosphatase
|
Inflammation/Immunology
|
|
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC50 values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes .
|
- HY-P11586
-
|
|
Amylin Receptor
|
Metabolic Disease
|
|
San45 is a nonselective dual amylin and calcitonin receptor agonist (DACRA) with nonselective potency relative to calcitonin receptor (CTR) and amylin 1 receptor (AMY₁R), and acts as a stabilizer of receptor-ligand complex and prolonged activator of cAMP signaling. San45 carries a conjugated lipid modification that can be used for the research of obesity .
|
- HY-P11625
-
|
|
RXFP Receptor
|
Cardiovascular Disease
|
|
R9-13 is a fatty acid-conjugated relaxin and an agonist of LGR7 (RXFP1). R9-13 induces sustained pubic symphysis elongation in estrogen-pretreated mice. R9-13 exhibits long-acting pharmacokinetic profiles in rodents, with in vivo activity lasting up to one week after administration. R9-13 can be used in studies related to acute heart failure .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P0014S1
-
|
|
|
Liraglutide- 13C6, 15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014) . Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P0014AS
-
|
|
|
Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
-
- HY-P0014S2
-
|
|
|
Liraglutide- 13C6, 15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-167015
-
|
|
|
Cationic Lipids
|
|
1O14 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 1O14 can be used in the preparation of liposomes .
|
-
- HY-167012
-
|
|
|
Cationic Lipids
|
|
306Oi9-cis2 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. 306Oi9-cis2 can be used in the preparation of liposomes .
|
-
- HY-167004A
-
|
|
|
Cationic Lipids
|
|
IAJD249 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD249 can be used in the preparation of liposomes .
|
-
- HY-167004
-
|
|
|
Cationic Lipids
|
|
IAJD93 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. IAJD93 can be used in the preparation of liposomes .
|
-
- HY-167003
-
|
|
|
Cationic Lipids
|
|
L16 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. L16 can be used in the preparation of liposomes .
|
-
- HY-167011
-
|
|
|
Cationic Lipids
|
|
Al-28 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. Al-28 can be used in the preparation of liposomes .
|
-
- HY-167002
-
|
|
|
Cationic Lipids
|
|
RM 137-15 is an ionizable lipid. The ability of ionizable lipids to form unstable non-bilayer structures at acidic pH is key for endosomal escape and cytosolic delivery of RNA. RM 137-15 can be used in the preparation of liposomes .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
